120 related articles for article (PubMed ID: 34031553)
21. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
Ghobadi A; Milton DR; Gowda L; Rondon G; Chemaly RF; Hamdi A; Alousi A; Afrough A; Oran B; Ciurea S; Kebriaei P; Popat UR; Qazilbash MH; Shpall EJ; Champlin RE; Bashir Q
Curr Res Transl Med; 2019 May; 67(2):51-55. PubMed ID: 30683577
[TBL] [Abstract][Full Text] [Related]
22. Donor T-cell chimerism and early post-transplant cytomegalovirus viremia in patients treated with myeloablative allogeneic hematopoietic stem cell transplant.
Taimur S; Askar M; Sobecks R; Rybicki L; Warshawsky I; Mossad S
Transpl Infect Dis; 2014 Feb; 16(1):61-6. PubMed ID: 24251680
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
24. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
[TBL] [Abstract][Full Text] [Related]
25. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
[TBL] [Abstract][Full Text] [Related]
26. Association between the kinetics of cytomegalovirus reactivation in terms of the area under the curve of cytomegalovirus antigenemia and non-relapse mortality after allogeneic hematopoietic stem cell transplantation.
Takeshita J; Kimura SI; Nakasone H; Kawamura S; Nakamura Y; Kawamura M; Yoshino N; Misaki Y; Yoshimura K; Matsumi S; Gomyo A; Tamaki M; Akahoshi Y; Kusuda M; Kameda K; Wada H; Sato M; Kako S; Kanda Y
Transpl Infect Dis; 2021 Oct; 23(5):e13715. PubMed ID: 34437758
[TBL] [Abstract][Full Text] [Related]
27. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center.
Rowe RG; Guo D; Lee M; Margossian S; London WB; Lehmann L
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1275-1283. PubMed ID: 27090959
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells.
Ozdemir E; St John LS; Gillespie G; Rowland-Jones S; Champlin RE; Molldrem JJ; Komanduri KV
Blood; 2002 Nov; 100(10):3690-7. PubMed ID: 12393402
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
31. The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.
Jain NA; Lu K; Ito S; Muranski P; Hourigan CS; Haggerty J; Chokshi PD; Ramos C; Cho E; Cook L; Childs R; Battiwalla M; Barrett AJ
Cytotherapy; 2014 Jul; 16(7):927-33. PubMed ID: 24831837
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
35. Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation.
Wagner-Drouet E; Teschner D; Wolschke C; Janson D; Schäfer-Eckart K; Gärtner J; Mielke S; Schreder M; Kobbe G; Kondakci M; Hilgendorf I; von Lilienfeld-Toal M; Klein S; Heidenreich D; Kreil S; Verbeek M; Grass S; Ditschkowski M; Gromke T; Koch M; Lindemann M; Hünig T; Schmidt T; Rascle A; Guldan H; Barabas S; Deml L; Wagner R; Wolff D
Haematologica; 2021 Feb; 106(2):363-374. PubMed ID: 31879324
[TBL] [Abstract][Full Text] [Related]
36. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
[TBL] [Abstract][Full Text] [Related]
37. [Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co-activation of cytomegalovirus and Epstein-Barr virus].
Song T; Chen G; Zhang X; Xu Y; Chen J; Wang Y; Ye L; Xu J; Wu D; Miao J
Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3135-9. PubMed ID: 25573307
[TBL] [Abstract][Full Text] [Related]
38. Correlations of human herpesvirus 6B and CMV infection with acute GVHD in recipients of allogeneic haematopoietic stem cell transplantation.
Wang LR; Dong LJ; Zhang MJ; Lu DP
Bone Marrow Transplant; 2008 Nov; 42(10):673-7. PubMed ID: 18695666
[TBL] [Abstract][Full Text] [Related]
39. Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation.
Hammerstrom AE; Lombardi LR; Pingali SR; Rondon G; Chen J; Milton DR; Chemaly RF; Champlin RE; Gulbis A; Ciurea SO
Biol Blood Marrow Transplant; 2018 Feb; 24(2):353-358. PubMed ID: 28986189
[TBL] [Abstract][Full Text] [Related]
40. The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation.
Knight A; Madrigal AJ; Grace S; Sivakumaran J; Kottaridis P; Mackinnon S; Travers PJ; Lowdell MW
Blood; 2010 Sep; 116(12):2164-72. PubMed ID: 20576814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
